Evidence map›Paper›PMID 36189881›Full record

ArticleProteomics2023

iBench: A ground truth approach for advanced validation of mass spectrometry identification method.

John A Cormican, Wai Tuck Soh, Michele Mishto, Juliane Liepe

Abstract read
In one paragraph

Article in Proteomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

John A CormicanMax-Planck-Institute for Multidisciplinary Sciences (MPI-NAT), Göttingen, Germany.
Wai Tuck SohMax-Planck-Institute for Multidisciplinary Sciences (MPI-NAT), Göttingen, Germany.
Michele MishtoCentre for Inflammation Biology and Cancer Immunology (CIBCI) & Peter Gorer Department of Immunobiology, King's College London, London, UK.
Juliane LiepeMax-Planck-Institute for Multidisciplinary Sciences (MPI-NAT), Göttingen, Germany.

Funding

Cancer Research UK 29686Cancer Research UK A29686Cancer Research UK C67500
6 · The paper itself

Abstract

The discovery of many noncanonical peptides detectable with sensitive mass spectrometry inside, outside, and on cells shepherded the development of novel methods for their identification, often not supported by a systematic benchmarking with other methods. We here propose iBench, a bioinformatic tool that can construct ground truth proteomics datasets and cognate databases, thereby generating a training court wherein methods, search engines, and proteomics strategies can be tested, and their performances estimated by the same tool. iBench can be coupled to the main database search engines, allows the selection of customized features of mass spectrometry spectra and peptides, provides standard benchmarking outputs, and is open source. The proof-of-concept application to tryptic proteome digestions, immunopeptidomes, and synthetic peptide libraries dissected the impact that noncanonical peptides could have on the identification of canonical peptides by Mascot search with rescoring via Percolator (Mascot+Percolator).

Indexed as

AlgorithmsTandem Mass SpectrometryDatabases, ProteinPeptidesSearch EngineSoftwarePeptidesbenchmarkingHLAimmunopeptidomemethod performanceproteomics

Identifiers

PMID36189881
PMCPMC10078205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.